Company Focus
Galderma
Latest Galderma News
Biotechnology
The US Food and Drug Administration (FDA) has approved Galderma’s Nemluvio (nemolizumab) as a pre-filled pen for subcutaneous injection for the treatment of adults with prurigo nodularis. 14 August 2024
Dermatology News
Insights
Company Spotlight
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.
Latest News & Features of interest to Galderma
Pharmaceutical
Italy’s Philogen and Indian drugmaker Sun Pharmaceutical Industries have submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for the approval of Nidlegy (daromun). 5 June 2024
Pharmaceutical
Privately-held company GAIA has had more than a front-row seat to observe the arrival of digital therapeutics and applications of AI in pharma over the past quarter century. 4 June 2024
Biotechnology
Researchers from UK-based biotech Immunocore Holdings shared new data at the American Society of Clinical Oncology (ASCO) meeting on Kimmtrak (tebentafusp-tebn), the first-ever treatment approved for metastatic uveal melanoma (mUM), showing there is treatment benefit for patients with stable disease and any confirmed tumor reduction. 3 June 2024
Biotechnology
Swiss pharma giant Novartis today announced new data that confirm the long-term efficacy and safety of remibrutinib, a highly selective Bruton’s tyrosine kinase (BTK) inhibitor, in chronic spontaneous urticaria (CSU). 31 May 2024
Pharmaceutical
Privately-held UK clinical-stage firm Soterios Pharma has announced positive multi-dose Phase II trial evaluating STS-01 as a treatment for mild/moderate alopecia areata (AA). 31 May 2024
Biotechnology
For 20 years, US pharma major AbbVie’s Humira (adalimumab) has been one of the world’s top-selling products. 29 May 2024
Biotechnology
US healthcare giant Johnson & Johnson has acquired Yellow Jersey Therapeutics (YJT), a wholly-owned subsidiary of Swiss biotech Numab Therapeutics. 29 May 2024
Biotechnology
Johnson & Johnson has entered into a definitive agreement to acquire Proteologix, the US healthcare giant revealed yesterday. 17 May 2024
Pharmaceutical
Dermatology company Verrica Pharmaceuticals has entered into an amendment to its existing licensing agreement with Torii Pharmaceutical. 16 May 2024
Pharmaceutical
Spanish dermatology company Almirall impressed investors with its financial results for the first quarter of 2024, which were presented on Monday. 13 May 2024
Latest In Brief for Galderma
Pharmaceutical
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
Latest Dermatology Ones To Watch News
Aspire Pharma, a UK-based niche generics business, has announced the acquisition of all assets from Canute Pharma, further expanding its product range. 4 October 2024
18 September 2024
13 August 2024
24 July 2024
17 May 2024
Dermatology Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze